Giiant Pharma benefits from expertise in personalized medicine, in the development of anti-inflammatory drugs to treat inflammatory diseases of the lower intestinal tract. The Company is developing potent inhibitors specific to the enzyme phosphodiesterase-4 (PDE4), which is markedly overexpressed in inflammation. Combined with innovative technology, the drug, in the form of a prodrug, is not absorbed and releases the specific active form in the colon at the site of inflammation. This helps prevent systemic exposure of the drug, makes it very safe while allowing doses to be increased for optimal effectiveness.
Sector of activity
- Life sciences